Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

被引:89
|
作者
Prado, JG
Wrin, T
Beauchaine, J
Ruiz, L
Petropoulos, CJ
Frost, SDW
Clotet, B
D'Aquila, RT
Martinez-Picado, J
机构
[1] Univ Autonoma Barcelona, Hosp Germans Trias Pujol, IrsiCaixa Fdn, Barcelona 08916, Spain
[2] Virolog Inc, San Francisco, CA USA
[3] Univ Calif San Diego, Dept Pathol, San Diego, CA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
amprenavir; HIV-1 drug resistance; lopinavir; protease inhibitors; replication capacity; viral fitness;
D O I
10.1097/00002030-200205030-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selective mutations. Methods: HIV-1(IIIB) variants derived from passage in increasing concentrations of amprenavir were studied, as well as 3'Gag/protease recombinants derived from them. These strains progressively accumulated mutations at codons 10, 46, 47, 50 and 84 in the protease as well as a p1/p6 cleavage site mutation at codon 449 in Gag. Their susceptibility (IC50) to various PI and their corresponding replication capacities were evaluated by a single-cycle growth assay and compared with measures using competitive cultures and p24 antigen production. Results: Amprenavir susceptibility decreased with increasing numbers of protease mutations. Changes in lopinavir susceptibility paralleled changes in amprenavir susceptibility. Certain amprenavir-selected mutants conferred greater than 10-fold cross-resistance to lopinavir, including PrL10F/M461/150V-GagL449F (19-fold) and PrL10F/M46I/147V/150V-GagL449F (31-fold). Moreover, one isolate with only two mutations in the protease (L10F/84V) and GagL449F displayed a 7.7-fold increase in lopinavir IC50. Low-level cross-resistance to ritonavir and nelfinavir was also observed. The replication capacity of viruses containing either 184V or 150V was at least 90% lower than the reference virus in the single-cycle assay. The order of relative replication capacity was wild-type > L10F > L10F/184V > L10F/M461/150V > L10F/M461/147V/150V. Conclusion: These results indicate that until more comprehensive genotype-phenotype correlations between amprenavir and lopinavir susceptibility are established, phenotypic testing may be preferable to genotyping to detect cross-resistance, and should be considered when switching patients from a failing amprenavir-containing regimen. This study also provides data on the concordance of replication capacity measurements generated using rapid single-cycle growth and competition assays. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:1009 / 1017
页数:9
相关论文
共 50 条
  • [21] HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics
    Wong-Sam, Andres
    Wang, Yuan -Fang
    Kneller, Daniel W.
    Kovalevsky, Andrey Y.
    Ghosh, Arun K.
    Harrison, Robert W.
    Weber, Irene T.
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2022, 117
  • [22] Resistant HIV strains often show cross-resistance to new drugs
    Bartlett, JG
    [J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1999, 8 (07) : 317 - 318
  • [23] Multiple drug resistant mechanisms against darunavir, amprenavir, and nelfinavir of HIV-1 PR
    Liu, Xiaoqing
    Dai, Qi
    Xiu, Zhilong
    [J]. JOURNAL OF MOLECULAR STRUCTURE, 2013, 1033 : 227 - 235
  • [24] Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1
    Polster, Robert
    Petropoulos, Christos J.
    Bonhoeffer, Sebastian
    Guillaume, Frederic
    [J]. MOLECULAR BIOLOGY AND EVOLUTION, 2016, 33 (12) : 3213 - 3225
  • [25] Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir
    Parimal Kar
    Volker Knecht
    [J]. Journal of Computer-Aided Molecular Design, 2012, 26 : 215 - 232
  • [26] Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir
    Kar, Parimal
    Knecht, Volker
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2012, 26 (02) : 215 - 232
  • [27] In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1
    Ren, C.
    May, S.
    Miletti, T.
    Bedard, J.
    [J]. ANTIVIRAL THERAPY, 2007, 12 (05) : S3 - S3
  • [28] In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1
    Ren, C.
    May, S.
    Miletti, T.
    Bedard, J.
    [J]. ANTIVIRAL THERAPY, 2007, 12 : S3 - S3
  • [29] In vitro HIV-1 cross-resistance against reverse transcriptase inhibitor-based microbicides
    Selhorst, P.
    Vazquez, A. C.
    Terrazas-Aranda, K.
    Michiels, J.
    Heyndrickx, L.
    Arien, K.
    Quinones-Mateu, M. E.
    Vanham, G.
    [J]. ANTIVIRAL THERAPY, 2010, 15 : A141 - A141
  • [30] CROSS-RESISTANCE BETWEEN AZT, DDL AND OTHER ANTIRETROVIRAL DRUGS IN PRIMARY ISOLATES OF HIV-1
    COX, SW
    APERIA, K
    SANDSTROM, E
    HOLMBERG, V
    MORFELDTMANSON, L
    BROSTROM, C
    WAHREN, B
    ALBERT, J
    [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1994, 5 (01): : 7 - 12